Source: International Congress 2018 – Imminent global problems in lung cancer require joint action: time for an international alliance!



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Nakanishi (Fukuoka, Japan). The Asian experience in co-existing lung cancer and interstitial lung disease. International Congress 2018 – Imminent global problems in lung cancer require joint action: time for an international alliance!

Member's Comments

No comment yet.

Related content which might interest you: The burden of emphysema on lung cancer prognosis Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Lung cancer and interstitial lung disease Source: International Congress 2018 – State of the art session: Thoracic oncology Year: 2018 A study on chemotherapy induced interstitial lung disease in patients with unresectable non-small cell lung cancer complicated by combined pulmonary fibrosis and emphysema Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Coexistence of chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer and impact on survival Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Lung nodules in a lung cancer screening program: incidence density of lung cancer in patients with COPD and/or emphysema Source: Annual Congress 2009 - Epidemiology and management of lung cancer Year: 2009 Clinicopathologic features of patients with non-small cell lung cancer and chronic obstructive pulmonary disease undergoing lung cancer surgery Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Bilateral lung cancer with COPD or metastatic disease Source: International Congress 2016 – CC4 Major challenges in thoracic surgical oncology Year: 2016 Siphonage lung disease Source: Virtual Congress 2020 – Respiratory critical care Year: 2020 Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Prevalence and characterization of interstitial lung disease in a lung cancer screening program Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Source: Eur Respir J, 50 (2) 1700050; 10.1183/13993003.00050-2017 Year: 2017 The management of children with interstitial lung disease Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018 The association of lung cancer with pulmonary fibrosis Source: ERJ Open Res, 8 (1) 00505-2021; 10.1183/23120541.00505-2021 Year: 2022 Coexistence of COPD in lung cancer patients Source: Eur Respir J 2001; 18: Suppl. 33, 66s Year: 2001 A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Prior lung disease and risk of lung cancer in women Source: Eur Respir J 2005; 26: Suppl. 49, 598s Year: 2005 A case series study on re-treatment to lung cancer after drug-induced interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Clinical and molecular analysis of lung cancer associated with fibrosing and diffuse interstitial lung disease. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021